Prev Close | 42.96 |
Open | 44.50 |
Day Low/High | 39.50 / 46.00 |
52 Wk Low/High | 13.77 / 71.50 |
Volume | 731.82K |
Prev Close | 42.96 |
Open | 44.50 |
Day Low/High | 39.50 / 46.00 |
52 Wk Low/High | 13.77 / 71.50 |
Volume | 731.82K |
Exchange | NASDAQ |
Shares Outstanding | 24.37B |
Market Cap | 1.15B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Stick to themes like biotechnology, SPACs, EV batteries, and others.
BioXcel Therapeutics and Avadel Pharmaceuticals are new additions to my personal portfolio based on their promising drug prospects.
Most notable is how the coronavirus issue is having no negative impact.